Company (Symbol) Product Description Indication Action (Date)
Maxim Pharmaceuticals Inc. (MAXM) Maxamine Histamine dihydrochloride; H2 receptor agonist Stage IV malignant melanoma Submitted NDA (7/10); FDA designated Maxamine for priority review; NDA was submitted in July (9/7); FDA s Oncologic Drugs Advisory Committee recommended against the NDA for Maxamine as an adjuvant to interleukin-2 to treat patients who have liver metastases (12/13)